{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:12:37Z","timestamp":1786119157764,"version":"build-2736575974"},"reference-count":11,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2007,12]]},"DOI":"10.1097\/rlu.0b013e3181596652","type":"journal-article","created":{"date-parts":[[2009,3,4]],"date-time":"2009-03-04T20:39:53Z","timestamp":1236199193000},"page":"933-934","source":"Crossref","is-referenced-by-count":11,"title":["Serum Sickness in a Patient With Follicular Lymphoma After Rituximab and Radioimmunotherapy With Ibritumomab Tiuxetan"],"prefix":"10.1097","volume":"32","author":[{"given":"Nicholas A.","family":"DeMonaco","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel A.","family":"Jacobs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-6-20210204","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1002\/1529-0131(200107)44:7<1717::AID-ART299>3.0.CO;2-C","article-title":"Serum sickness secondary to treatment with the murine-human chimeric antibody IDEC-C2B8 (rituximab).","volume":"44","author":"D'Arcy","year":"2001","journal-title":"Arthritis Rheum"},{"key":"R2-6-20210204","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1002\/ajh.10127","article-title":"Rituximab-induced serum sickness.","volume":"70","author":"Herishanu","year":"2002","journal-title":"Am J Hematol"},{"key":"R3-6-20210204","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1093\/annonc\/mdg488","article-title":"Delayed-type hypersensitivity reaction or serum sickness after rituximab treatment.","volume":"14","author":"Hellerstedt","year":"2003","journal-title":"Ann Oncol"},{"key":"R4-6-20210204","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.jpeds.2004.09.004","article-title":"Chronic immune thrombocytopenic purpura in children: assessment of rituximab treatment.","volume":"146","author":"Wang","year":"2005","journal-title":"J Pediatr"},{"key":"R5-6-20210204","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1093\/rheumatology\/keh470","article-title":"Serum sickness associated with rituximab in a patient with hepatitis C virus-related mixed cryoglobulinaemia.","volume":"44","author":"Catuogno","year":"2005","journal-title":"Rheumatology"},{"key":"R6-6-20210204","doi-asserted-by":"crossref","first-page":"2740","DOI":"10.1002\/art.21260","article-title":"Rituximab treatment in patients with primary Sjogren's syndrome: an open-label phase II study.","volume":"52","author":"Pijpe","year":"2005","journal-title":"Arthritis Rheum"},{"key":"R7-6-20210204","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1136\/ard.2004.029694","article-title":"Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases.","volume":"64","author":"Gottenberg","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"R8-6-20210204","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.1182\/blood-2005-08-3518","article-title":"Prospective phase 1\/2 study of rituximab in childhood and adolescent chronic immune thrombocytopenic purpura.","volume":"107","author":"Bennett","year":"2006","journal-title":"Blood"},{"key":"R9-6-20210204","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1080\/10428190600565354","article-title":"Pegylated interferon plus rituximab in advanced stage, indolent lymphoma: is there CD20 antigen upregulation?","volume":"47","author":"Portlock","year":"2006","journal-title":"Leuk Lymphoma"},{"key":"R10-6-20210204","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1136\/ard.2006.057919","article-title":"Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjogren's syndrome.","volume":"66","author":"Seror","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"R11-6-20210204","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/j.1365-2141.2006.06214.x","article-title":"Rituximab-induced serum sickness.","volume":"135","author":"Schutgens","year":"2006","journal-title":"Br J Haematol"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00003072-200712000-00006","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T17:41:08Z","timestamp":1786038068000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00003072-200712000-00006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,12]]},"references-count":11,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2007]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0b013e3181596652","relation":{},"ISSN":["0363-9762"],"issn-type":[{"value":"0363-9762","type":"print"}],"subject":[],"published":{"date-parts":[[2007,12]]}}}